GAMMA Investing LLC Boosts Holdings in Edwards Lifesciences Co. (NYSE:EW)

GAMMA Investing LLC grew its position in Edwards Lifesciences Co. (NYSE:EW) by 12.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,587 shares of the medical research company’s stock after acquiring an additional 292 shares during the quarter. GAMMA Investing LLC’s holdings in Edwards Lifesciences were worth $247,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. DSM Capital Partners LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at $28,000. Turtle Creek Wealth Advisors LLC purchased a new position in Edwards Lifesciences in the 4th quarter worth about $34,000. Pingora Partners LLC bought a new stake in Edwards Lifesciences during the 4th quarter valued at about $38,000. Operose Advisors LLC boosted its position in Edwards Lifesciences by 247.0% in the 3rd quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after buying an additional 452 shares during the period. Finally, SRS Capital Advisors Inc. grew its stake in Edwards Lifesciences by 292.6% in the 3rd quarter. SRS Capital Advisors Inc. now owns 636 shares of the medical research company’s stock worth $44,000 after acquiring an additional 474 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of a number of research reports. Royal Bank of Canada boosted their price target on Edwards Lifesciences from $95.00 to $101.00 and gave the company an “outperform” rating in a report on Monday, April 15th. The Goldman Sachs Group assumed coverage on Edwards Lifesciences in a report on Thursday, May 30th. They issued a “buy” rating and a $107.00 target price for the company. Wells Fargo & Company raised their price target on Edwards Lifesciences from $94.00 to $99.00 and gave the company an “overweight” rating in a research note on Friday, April 26th. Citigroup raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and upped their price objective for the stock from $98.00 to $105.00 in a research note on Wednesday, May 22nd. Finally, Stifel Nicolaus raised their target price on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a “hold” rating in a research report on Friday, April 26th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and fourteen have given a buy rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $95.06.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $88.86 on Friday. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.67 and a current ratio of 3.75. The company has a market cap of $53.55 billion, a PE ratio of 38.30, a P/E/G ratio of 3.24 and a beta of 1.11. The business has a 50-day simple moving average of $87.45 and a two-hundred day simple moving average of $84.28.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. As a group, equities analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current fiscal year.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Jean-Luc M. Lemercier sold 14,400 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the sale, the vice president now owns 173,849 shares in the company, valued at approximately $14,639,824.29. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $87.54, for a total transaction of $437,700.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares in the company, valued at $4,108,777.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total transaction of $1,212,624.00. Following the completion of the sale, the vice president now directly owns 173,849 shares in the company, valued at $14,639,824.29. The disclosure for this sale can be found here. Insiders sold 127,104 shares of company stock worth $11,267,464 in the last 90 days. Insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.